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Abstract: Amphotericin B deoxycholate (AmB), a classic antifungal drug, remains the 
initial treatment of choice for deep fungal infections, but it is not appropriate for treatment of 
cryptococcal meningitis due to its inability to pass through the blood–brain barrier (BBB). We 
examined the efficacy of amphotericin B-polybutylcyanoacrylate nanoparticles (AmB-PBCA-
NPs) modified with polysorbate 80 that had a mean particle diameter less than 100 nanometers 
(69.0 ± 28.6 nm). AmB-PBCA-NPs were detected in the brain 30 minutes after systemic 
administration into BALB/c mice and had a higher concentration than systemically administered 
AmB liposome (AmB-L, P , 0.05); AmB was not detected in the brain. Following infection for 
24 hours and then 7 days of treatment, the survival rate of mice in the AmB-PBCA-NP group 
(80%) was significantly higher than that of the AmB (0%) or AmB-L (60%) treatment groups. 
Fungal load was also lower when assessed by colony-forming unit counts obtained after plating 
infected brain tissue (P , 0.05). Our study indicates that AmB-PBCA-NPs with polysorbate 80 
coating have the capacity to transport AmB across the BBB and is an efficient treatment against 
cryptococcal meningitis in a mouse model.
Keywords: cryptococcal meningitis, polybutylcyanoacrylate (PBCA), nanoparticles, brain 
targeting
Introduction
The incidence of deep fungal infection has risen significantly in response to the 
increased prescription of antibiotics in patients treated with immunosuppressive drugs, 
or immunosuppression following organ transplantation, malnutrition, or diabetes.1 
Although amphotericin B deoxycholate (AmB) continues to be the gold standard for 
treatment by selectively binding to ergosterol in the fungal cell membrane, which 
results in the leakage of intracellular contents and cellular death,2 clinical application 
of AmB against cryptococcal meningitis is limited due to its inability to pass through 
the blood–brain barrier (BBB).3,4 In addition, serious side effects and toxicity, including 
acute infusion reactions (nausea, vomiting, rigor, fever, or hypoxia) and dose-dependent 
nephrotoxicity, limit the use of AmB.2,5 Incorporation of drugs into liposomes mini-
mizes toxicity without a loss of pharmacologic effect.6 Lipid modifications, including 
amphotericin B liposome (AmB-L), amphotericin B lipid complex, and amphotericin 
B colloidal dispersions, were developed to improve the tolerance profile of AmB and 
improve access across the BBB. Compared with the recommendations for AmB, the 
lipisome-incorporated forms can be administered at a five to seven times higher dos-
age and contribute to better efficacy, but the frequency of infusion-related adverse 
events remains a problem.7 These issues have necessitated the need for a better drug International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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delivery medium that provides permeability to the BBB and 
minimizes AmB toxicity, as well as effective control of the 
cryptococcal meningitis infection.
Techniques using drug–nanoparticle complexes have been 
developed recently as drug delivery systems, and a number of 
materials have emerged as potential brain-targeting   carriers. 
Polybutylcyanoacrylate (PBCA) has been suggested as a 
good sustained drug vehicle that potentially allows differ-
ent substances to pass through the BBB and can be widely 
used for both treatment and diagnostic purposes via oral or 
intravenous administration.8–11
Compared with some other carriers, PBCA was con-
firmed to ameliorate BBB permeability by 3- to 16-fold.12 
Kreuter and Gelperina9 used PBCA to transport doxorubicin 
and found that it significantly increased the survival times 
of rats with cerebral cancer, leading to complete tumor 
remission in 20%–40% of the animals. The use of nano-
particles also considerably reduced the effective dosage of 
doxorubicin, which is limited due to its testicular toxicity 
and cardiotoxicity.9 Previous studies have not focused on 
antifungal agents.
Polysorbate 80 enhances the central nervous system 
uptake of drug nanoparticles in both human and bovine 
primary brain capillary endothelial cells, which suggests 
that it is a preferred surfactant.13,14 When coated with 
polysorbate 80, the accumulation of nanoparticles in the 
reticuloendothelial system decreased by 40% 1 hour after 
injection,11 and the drug concentration in the brain increased 
by 20-fold.13
Previously, we employed polylactic acid-b-polyethylene 
glycol (PLA-b-PEG) as a way of loading AmB in order to 
achieve penetration across the BBB.15 In this present study, 
we prepared AmB-PBCA-nanoparticles (AmB-PBCA-NPs) 
coated with polysorbate 80 in order to explore another 
method of encapsulating AmB within the polymer matrix 
and to determine their effectiveness in permeating through 
the brain tissue.
Materials and methods
chemicals and reagents
AmB and AmB-L were ordered from New Pioneer Phar-
maceutical Co. Ltd (Shanghai, People’s Republic of China). 
α-butyl-cyanoacrylate (α-BCA, Batch No: 20050508) was 
obtained from Beijing Shunkang Co. Ltd (Beijing, People’s 
Republic of China). Polysorbate 80, Dextran T-70, and acetic 
acid were purchased from Shanghai Chemical Reagent Co. 
Ltd (Shanghai).
Preparation of AmB-PBcA-NPs and size 
determination
AmB-PBCA-NPs were prepared as follows. Unloaded 
PBCA-NPs were produced by spontaneous anionic polym-
erization of α-BCA (20 mg/mL) with 300 mg of Dextran 
T-70 during magnetic stirring at room temperature for 
4 hours. Twenty milligrams of AmB were dissolved in the 
mixed solvents for 4 hours, and then 0.1 mL of polysorbate 
80 was added dropwise to 10 mL of the colloidal solution. 
After sufficient mixing, the complex was incubated at 37°C 
for at least 2 hours. Prepared AmB-PBCA-NPs were stored 
at 4°C prior to use.
size distribution and morphology  
of AmB-PBcA-NP
The AmB-loaded nanoparticle suspension was homogenized 
by sonication for 20 minutes. The diameter and size distri-
butions of the particles were determined by a Coulter Laser 
Granulometer (Zetasizer, Malvern Instruments, Malvern, 
UK) at room temperature.
After homogenization, a drop of the nanoparticle suspen-
sion was loaded onto a copper halftone grid and stained by 
a 1% (wt) phosphotungstic acid solution. The sample was 
characterized by a JEM-100CXII transmission electron 
microscope (Hitachi, Tokyo, Japan) using an electron beam 
accelerating voltage of 100 kV .
encapsulation rate of AmB into  
AmB-PBcA-NPs
The spectrum of AmB-PBCA-NPs was analyzed and 
calibrated at a wavelength of 405 nm (UV-256, Shimadzu, 
Japan). The encapsulation rate of AmB within the poly-
mer matrix was calculated by the formula: entrapment 
efficiency (%) = (weight of loaded AmB)/(weight of AmB 
input) × 100%.
Animals and fungus
Healthy BALB/c mice weighing 20 ± 5 g (provided by the 
Laboratory Animal Center of Academia Sinica, Shanghai, 
People’s Republic of China) were used in the biodistribution 
and therapeutic studies. All mice were housed in a pathogen-
free environment and received sterilized food and water. All 
procedures complied with the Guide for the Care and Use of 
Laboratory Animals.
The Cryptococcus neoformans 30629B suspension used 
for the inoculation was prepared by diluting the fungus with 
sterile saline to a final concentration of 5.0 × 108 cell/mL, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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which was determined using a hemocytometer and 
microscopic observation.
chromatography
Analytical high-performance liquid chromatography (HPLC) 
with an ultrabase C18 reversed-phase column (Dikma, Japan) 
was used for chromatographic analysis (mobile phase: 
acetonitrile–water [40:60] acetic acid [4%], flow rate: 
0.9 mL/minute, ultraviolet detection wavelength: 405 nm, 
and column temperature: 37°C).
Pharmacokinetic studies
An injection of AmB (1 mg/kg), AmB-PBCA-NPs (3 mg/kg), 
or AmB-L (10 mg/kg) was administered to mice through the 
tail vein. Data were collected at 0.5 hours, 1 hour, 3 hours, 
6 hours, 12 hours, 24 hours, and 48 hours (n = 28/group, 
n = 4/time point). The thorax was opened and the animals 
perfused through the heart with saline to wash out the remain-
ing AmB. Tissues were then homogenized with sterile saline, 
and the supernatant of the homogenate was extracted with 
an equal volume of acetonitrile (for the brain: 1 µg/mL; for 
the heart, lung, liver, and kidney: 2 µg/mL). The organic 
phase was analyzed by HPLC with quercetin as an internal 
standard.
effect of AmB-PBcA-NPs against murine 
cryptococcal meningitis
BALB/c mice were anesthetized with ethyl ether and then 
inoculated with the C. neoformans suspension (concentration 
5 × 108 cell/mL, dose 5 µL/20 g) through foramen magnum 
24 hours after an intraperitoneal injection of cyclophosph-
amide (2 µg /20 g; Jiangsu Hengrui Medical Co. Ltd, Jiangsu, 
People’s Republic of China; H 32020857).
Twenty-four hours after the fungal inoculation, an injec-
tion of i) AmB (1 mg/kg), ii) AmB-PBCA-NPs (3 mg/kg), 
iii) AmB-L (10 mg/kg), or iv) saline was administered 
through the tail vein and then daily injections maintained 
for 7 consecutive days. Twenty-four hours after the first 
injection (day 1) and last injection (day 7), the mice (n = 10/
group, n = 5/time point) were sacrificed and the brains were 
dissected, weighed, and homogenized with sterile saline 
(2 mL/g). The homogenate was serially diluted with sterile 
saline, then 0.1 mL of the suspension was inoculated onto 
sabouraud dextrose agar plates and incubated at 37°C for 
24 hours and the number of colonies counted.
In a separate experiment, the mice were inoculated with 
the C. neoformans suspension and 24 hours later given 
daily injections of i) AmB (1 mg/kg), ii) AmB-PBCA-NPs 
(3 mg/kg), iii) AmB-L (10 mg/kg), or iv) saline for 7 days. 
The survival rates of the mice (n = 20/group) were observed 
for 20 days after the beginning of treatment.
routine blood tests to determine the 
effect of treatment on the liver, kidney, 
and blood components
Mice were injected daily via the tail vein with i) AmB 
(1 mg/kg), ii) AmB-PBCA-NPs (3 mg/kg), iii) PBCA-NPs 
(blank nanoparticles without AmB, 3 mg/kg), and iv) polysor-
bate 80 (1%) (n = 10/group). Polysorbate 80 replaced saline 
as a control in order to verify that it had no effect on the 
general health of the animals. Orbital blood was collected 
1 day before, 1 day after, or 7 days after drug administration. 
Blood indices were determined for erythrocytes (red blood 
cells [RBCs]), leucocytes (white blood cells [WBCs]), and 
platelets (PLTs) using an automatic hemocytometer. Whole 
blood was centrifuged at 14000 rpm for 10 minutes and stored 
at -20°C prior to routine tests for liver function using ala-
nine aminotransterase (ALT) and aspartate aminotransferase 
(AST), and kidney function using blood urea nitrogen (BUN) 
and creatinine (Cr).
statistical analysis
All the aforementioned experiments were repeated three 
times. The differences between experimental groups were 
analyzed by analysis of variance with a post hoc test. All 
values are presented as the mean ± standard deviation, 
and results were considered statistically significant with 
P # 0.05.
Results
characteristics of AmB-PBcA-NPs
The mean diameter of the prepared AmB-PBCA-NPs was 
69.0 ± 28.6 nm, and they were spherical in shape (Figure 1). 
After polysorbate 80 modification, the nanoparticles were 
slightly less spherical, but the sizes of the particles were 
not significantly different. The mean encapsulation rate of 
AmB-PBCA-NPs was 56.0% ± 1.4%.
Pharmacokinetic study
The concentration of AmB in tissues was determined by 
HPLC with quercetin as an internal standard (Figure 2). The 
detection limit of AmB was 10 ng/mL, and the interday and 
intraday coefficients of variation were 5% or less between 
5 ng/mL and 200 ng/mL.International Journal of Nanomedicine 2011:6
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Figure 1 size distribution and morphology of amphotericin B-polybutylcyanoacrylate 
nanoparticles (AmB-PBcA-NPs). A) The mean diameter of polysorbate 80-coated 
AmB-PBcA-NPs determined by a coulter Laser granulometer was 69.0 ± 28.6 nm. 
B)  AmB-PBcA-NPs  without  polysorbate  80  coating  were  spherical  in  shape.   
C) AmB-PBCA-NPs after polysorbate 80 modification had a more elliptical shape 
but were of a similar size to uncoated particles (×50,000).
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Figure 2 Amphotericin B (AmB) levels in various tissues following injections 
of AmB, amphotericin B-polybutylcyanoacrylate nanoparticles (AmB-PBcA-NPs), 
or amphotericin B liposome (AmB-L). A) high-performance liquid chromatogram 
showing the presence of AmB in brain tissue. The detection limit of AmB was 
10 ng/mL, and the interday and intraday coefficients of variation were 5% or 
less between 5 ng/mL and 200 ng/mL. B) AmB was not detected in the brain 
tissue of mice treated with noncomplexed AmB but was found 30 minutes after 
AmB-PBcA-NP treatment and 3–6 hours after AmB-L treatment (n = 28/group). 
C–D) The concentration of AmB in various tissues is shown after AmB, AmB-L, 
and AmB-PBcA-NP treatment, respectively (n = 28). AmB was concentrated 
mainly in the liver; note also the higher lung concentration when using AmB-
PBcA-NPs.
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AmB was not detected in the brains of AmB-treated 
mice. The drug concentration in the brain tissue of the 
AmB-PBCA-NP group was present within 0.5 hours after 
injection and reached a peak value of 133 ± 4 ng/g by 3 hours 
and then gradually fell to 66.1 ± 1.1 ng/g by 48 hours after International Journal of Nanomedicine 2011:6
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Figure  4  Fungal  load  in  the  brain  of  Balb/c  mice  infected  with  Cryptococcus 
neoformans treated with amphotericin B (AmB), amphotericin B liposome (AmB-L), 
amphotericin B-polybutylcyanoacrylate nanoparticles (AmB-PBcA-NPs), or saline.
Notes: Data were assessed from plated brain tissue and the number of colony-
forming units (cFU). *P , 0.05, value vs AmB group; b*P , 0.05, value vs AmB-L 
group (n = 10/group).
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Therapeutic efficacy of AmB-PBCA-NPs 
against murine cryptococcal meningitis
Mice inoculated with C. neoformans began to die 3 days 
after the injection, and the majority of animals had died by 
day 6, reaching a maximum on day 14 (80%) without further 
death until day 20 (Figure 3). Inoculated animals treated with 
AmB showed a similar trend, although were slightly delayed 
compared with the saline-treated mice, and the majority 
of animals were dead by day 10. Unlike the saline-treated 
mice, all of those treated with AmB had succumbed to the 
infection by day 15. In contrast, the AmB-L treatment group 
showed a slower decline in numbers beginning on day 2 and 
lasting until day 14, with a maintained 60% survival rate 
thereafter. Death did not occur until day 4 in mice treated 
with   AmB-PBCA-NPs, and there was a slower decline in 
numbers until day 10, with a maintained survival rate of 80% 
for the remainder of the experiment.
C. neoformans burden in the brain
The amount of C. neoformans remaining in the brain 
after 1 day and 7 days of treatment was assessed and 
expressed as log10 (mean colony-forming units/brain in each 
group ±   standard error). AmB-treated animals showed a sig-
nificantly lower (P , 0.05) fungal load on day 1 compared 
with saline-injected animals, but this had increased by 7 days 
after the consecutive injection and was not different from 
that seen in the saline-injected animals (Figure 4). AmB-L-
treated animals had significantly lower (P , 0.05) fungal 
loads for day 1 and day 7 compared with the saline- and 
AmB-treated animals, but they were significantly higher 
(P , 0.05) than those seen in AmB-PBCA-NP-treated 
animals. AmB-  PBCA-NP treatment was clearly the most 
the   injection. In contrast, AmB was not detected until 3 hours 
after the injection in the brains of the AmB-L-treated mice 
and reached a peak of 67.2 ± 1.9 ng/g at 24 hours before 
falling to slightly lower values at 48 hours (61.1 ± 1.6 ng/g). 
Peak values of AmB in AmB-PBCA-NP-treated mice were 
significantly higher than peak values in AmB-L-treated mice 
(P , 0.01, n = 28/group) (Figure 3), although AmB concen-
tration was not significantly different by 48 hours.
The concentration of AmB was highest in liver tis-
sue and gradually increased, reaching a peak at 12 hours 
(24.6 ± 0.5 µg/g, n = 28/group) before falling to lower levels 
at 48 hours. Lower levels of AmB were seen in the heart, lung, 
spleen, and kidney (,3 µg/g), although the concentration of 
AmB was noticeably higher in lung and heart tissue between 
12 hours and 24 hours. In contrast, with the exception of the 
heart, the concentration of AmB-L showed a much earlier 
increase in all tissue and peaked between 1 hour and 3 hours 
before falling to lower levels at 48 hours. Similar to AmB, the 
concentration of AmB-L was highest in the liver and peaked 
at 1 hour (6.8 ± 0.1 µg/g) after the injection and consider-
ably earlier when compared with that seen in the brain tissue 
(1 hour vs 12 hours), albeit at a much lower concentration. 
AmB-L concentration in the heart steadily declined from that 
seen at 0.5 hours. The concentration of AmB-PBCA-NPs 
also showed an early peak in the liver tissue 1 hour after 
the injection (9.7 ± 0.3 µg/g) but fell more rapidly to very 
low levels at 3 hours compared with AmB-L. The peak also 
occurred earlier than that observed in the brain tissue but, 
unlike that seen in the brain tissue, was not sustained over 
the next 48 hours. In contrast to AmB and AmB-L, AmB-
PBCA-NP levels were noticeably higher in lung tissue, with 
a peak (6.3 ± 0.4 µg/g) at 1 hour after the injection, but were 
absent in spleen and kidney tissue (Figure 4).
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Figure  3  survival  rate  of  mice  under  different  treatments.  All  amphotericin  B 
(AmB)-treated mice died within 15 days. In contrast, 80% of the mice survived after 
amphotericin B-polybutylcyanoacrylate nanoparticle (AmB-PBcA-NP) injections, and 
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effective in reducing fungal loads on both days compared 
with saline injections (1 day: 4.61 ± 0.01 vs 5.63 ± 0.07; 
7 days: 3.93 ± 0.07 vs 5.74 ± 0.05, respectively).
Blood component analysis
In order to investigate the adverse effects of different 
treatments, various indices were measured for the liver, 
kidney, and blood system (see Figures 5 and 6). After 
AmB administration, WBC and PLT counts showed a 
significant increase by day 7 compared with   preinjection 
values (-1 day; P , 0.01). WBC counts were also 
elevated on days 1 and 7 when animals were treated with 
Amb-PBCA-NPs and PBCA-NPs (P . 0.05) but to a 
lesser degree compared with AmB; polysorbate 80 had 
no effect on WBC counts. In contrast, AmB-PBCA-NPs, 
PBCA-NPs, and polysorbate 80 treatments had no effect 
on PLT counts. RBC counts were significantly lower on 
days 1 and 7 compared with pretreatment (P , 0.01) for 
AmB, AmB-PBCA-NPs, and PBCA-NPs, with AmB hav-
ing the largest effect. Similarly, hemoglobin (Hb) values 
were significantly lower in the AmB and AmB-PBCA-NP 
treatment groups (P , 0.01), but Hb was not affected by 
PBCA-NP or polysorbate 80 treatments. The significant 
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differences between AmB and AmB-PBCA-NP treatment 
groups (P , 0.05) indicate that encapsulation by PBCA-
NPs effectively reduced the side effects of AmB on the 
blood system.
ALT and AST values, indicative of liver function, were 
significantly higher on days 1 and 7 following injections of 
AmB (P , 0.01) and AmB-PBCA-NPs (P , 0.05) compared 
with the preinjection values. AmB values were also signifi-
cantly higher compared with AmB-PBCA-NPs (P , 0.05). 
In contrast, PBCA-NPs and polysorbate had no effect on 
either ALT or AST values, which suggests that the noted 
changes are due to AmB itself.
A similar situation was found when measuring the kid-
ney indicators BUN and Cr, in that BUN was significantly 
higher after AmB treatment compared with the preinjection 
values (P , 0.01), although no change was seen after AmB-
PBCA-NP, PBCA-NP, or polysobate injections. Cr values 
were also higher following AmB treatment but, due to the 
variability in the samples, were not significant. Although 
Cr values were significantly (P , 0.05) higher on day 7 
  following polysorbate 80 injections, these values still appear 
to be within the variability of preinjection values in other 
animals and therefore may not represent a real change in 
kidney function in these animals.
Discussion
The clinical application of AmB is limited by its cytotoxicity. 
More importantly, impermeability across the BBB results in 
a low therapeutic efficacy for the treatment of cryptococcal 
meningitis.16 To overcome these problems, intrathecal injec-
tion was developed clinically, but most patients in China are 
reluctant to pursue this treatment due to the risks involved and 
the inconvenience. Several substitutes for AmB have been 
commercialized in a search for better therapeutic effects and 
a safer application.17,18
PBCA nanoparticles have been intensively investigated 
since the first study in 1995, showing that nanoparticles 
coated with the nonionic surfactant polysorbate 80 are able 
to cross the BBB.19 Recent reports have confirmed that PBCA 
is an excellent brain-targeting medium with which to deliver 
therapeutic or diagnostic agents.12 We successfully prepared 
AmB-PBCA-NPs coated with polysorbate 80. Electron 
microscopy showed the drug–nanoparticle complex had a 
uniform diameter that was less than 100 nm (Figure 1), which 
meets the pharmaceutical requirements for therapeutic usage. 
Delayed-release tendency tests in vitro showed the drug could 
be released slowly within 24 hours (data not shown).
AmB was not detected in the brain, indicating that AmB 
on its own does not readily cross the BBB. After encap-
sulation by PBCA and polysorbate 80 modification, the 
drug concentration in the brain was detectable 30 minutes 
after administration and increased to maximum by 3 hours 
(133 ± 4 ng/g), which was significantly higher than that of 
AmB-L. In the previous study, we successfully prepared 
AmB-PLA-b-PEG-NPs with a polysorbate 80 modification. 
HPLC data showed that it had a lower concentration in brain 
tissue than AmB-PBCA-NPs 3 hours after the injection 
(126.1 ± 3.5 vs 132.5 ± 3.7, P = 0.883 . 0.05), with the 
peak concentration appearing at 12 hours (160.4 ± 3.5 vs 
111.6 ± 3.3, P = 0.018 , 0.05). Although the mechanism by 
which these complex nanoparticles cross the BBB has not 
been fully elucidated, many studies have given a number of 
possible mechanisms. Ramge et al13 suggested that it could 
be attributed to endocytosis by endothelial cells of the blood 
vessels within the brain parenchyma. Kreuter20 found that 
apolipoprotein E (ApoE) plays a vital role in the transport of 
low-density lipoproteins into the brain, and polysorbate 80 
acts mainly as an anchor for the Apo-coated nanoparticles. 
Therefore, the nanoparticles mimic low-density lipoproteins 
and interact with the brain capillary endothelial cells, finally 
transferring the drug into the brain via receptor-mediated 
endocytosis. A recent study examined the effectiveness of 
other apolipoproteins, such as ApoE3, B-100, and A-I, in 
brain targeting,21 showing the existence of more than one 
nanoparticle–brain endothelium interaction mechanism. We 
also hypothesize that, due to the small size of the complex 
particles, many of them escape uptake by phagocytic cells 
of the liver, spleen, and reticuloendothelial system and may 
account for the significantly lower accumulation of AmB 
found in these tissues compared with noncomplexed AmB 
(Figure 2). The absence of AmB-PBCA-NPs in kidney tissue 
may be explained as a result of a lower filtration rate through 
the renal tubules.
Most mice with cryptococcal meningitis started to die 
2–4 days after the spore challenge with a 20% survival rate 
after 20 days. Animals treated with AmB-PBCA-NPs exhib-
ited improved clinical status (such as appetite, fur color, and 
condition; data not shown), a higher survival rate, and a sig-
nificant reduction in the burden of C. neoformans remaining 
in the brain 1 week after the cessation of therapy. A similar 
survival rate (80%) and fungal burden were observed in 
AmB-b-PEG-NP-treated mice.15 AmB-L treatment was also 
efficacious, but to a lesser degree compared with AmB-
PBCA-NP treatment. The high death rate of infected mice International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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with AmB treatment may be due to the dosage of 1 mg/kg, 
which is likely to cause the side effects previously mentioned. 
This is also reflected in the blood analysis data where AmB 
had a significant effect on all the tested parameters. Indeed, it 
was noted that injections of AmB must be given very slowly 
or the death of the animal results, which did not happen with 
AmB-PBCA-NP administration. Good encapsulation by the 
nanovector allows sustained drug release over a period of 
hours, preventing a rapid rise in plasma concentration.
PBCA-NPs were first prepared by Couvreur et al22 in 
1979 and were considered to have relatively low toxicity. 
Moreover, PBCA is among the most rapidly biodegrading 
synthetic polymers that undergo in vivo degradation by 
enzymatic ester hydrolysis, producing a primary alcohol-, 
butanol-, and water-soluble poly-2-cyanoacrylic acid. As a 
result of this rapid degradation, as well as the low molecu-
lar weight of the polymer in the nanoparticle, the polymer 
material is rapidly eliminated from the body. The main 
advantages of using PBCA-NPs for brain targeting include 
their ability to deliver AmB to the brain without changing 
the drug’s original characteristics, as well as to decrease 
drug escape in the brain and reduce peripheral toxicity. AmB 
was encapsulated into nanoparticles evenly and stably and 
released gradually. Consequently, the direct interaction of 
AmB and cholesterol (similar constitution to ergosterol on 
the surface of erythrocytes) attenuated   accordingly. Thus, 
the toxicity to erythrocytes was significantly mitigated. In 
our study, although the side effects were evidently weak-
ened, there were still some changes in the blood system 
indices and liver function after AmB-PBCA-NP injection, 
which mainly arise because of the release of the encapsu-
lated AmB.
Conclusion
In conclusion, our study shows that PBCA can be used as an 
alternative delivery vehicle for the antifungal agent AmB. 
In addition, polysorbate 80 is necessary for efficient brain 
  targeting. More importantly, AmB-PBCA-NPs are able to 
reduce the toxicity of AmB to the liver, kidney, and blood 
system and increase the survival rates of mice with crypto-
coccal meningitis. The next challenge is to further design 
these drugs to ensure a balance between drug release and 
drug potency without tissue toxicity and to expand their 
applicability to fighting other forms of infection.
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